Trial
NCT03294694
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Dana-Farber Cancer Institute
Collaborators
Novartis
Condition
Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer
Intervention
Ribociclib
Why stopped
Safety Implications
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-31